Irgm2 and Gate-16 put a break on caspase-11 activation.
Journal
EMBO reports
ISSN: 1469-3178
Titre abrégé: EMBO Rep
Pays: England
ID NLM: 100963049
Informations de publication
Date de publication:
05 11 2020
05 11 2020
Historique:
pubmed:
3
11
2020
medline:
4
3
2021
entrez:
2
11
2020
Statut:
ppublish
Résumé
In infections caused by gram-negative bacteria, the bacterial cell wall component lipopolysaccharide (LPS) acts as a potent pathogen-associated molecular pattern (PAMP) that triggers the innate immune system. This is accomplished by two pattern recognition receptor systems. Toll-like receptor 4 (TLR4) senses extracellular LPS and induces a broad pro-inflammatory transcriptional program and also antiviral interferons. A complementary system detects intracellular LPS. As such, upon its release into the cytoplasm, LPS can directly engage the protease caspase-4 (caspase-11 in the murine system) and thereby trigger a pro-inflammatory cell death program known as pyroptosis (Rathinam et al, 2019). This is mediated by active caspase-4 cleaving its substrate gasdermin D (GSDMD). The thereby released N-terminal fragment of GSDMD inserts into the cell membrane and forms a cytotoxic pore. As a consequence, the cell ruptures and releases its pro-inflammatory content. In addition, the GSDMD pore results in potassium efflux that can activate the NLRP3 inflammasome. NLRP3 in turn activates caspase-1, which matures pro-IL-1β and pro-IL-18, further perpetuating the inflammatory nature of this cell death. Given its unconventional mode of NLRP3 activation, this pathway has been coined the non-canonical inflammasome.
Identifiants
pubmed: 33135287
doi: 10.15252/embr.202051787
pmc: PMC7645257
doi:
Substances chimiques
Inflammasomes
0
Interleukin-1beta
0
Intracellular Signaling Peptides and Proteins
0
Lipopolysaccharides
0
Phosphate-Binding Proteins
0
Caspases
EC 3.4.22.-
Dynamins
EC 3.6.5.5
Types de publication
News
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
e51787Commentaires et corrections
Type : CommentOn
Type : CommentOn
Informations de copyright
© 2020 The Authors.
Références
EMBO Rep. 2020 Nov 5;21(11):e50829
pubmed: 33124769
EMBO Rep. 2020 Nov 5;21(11):e50830
pubmed: 33124745
Nat Immunol. 2020 Aug;21(8):880-891
pubmed: 32541830
Nat Commun. 2020 Jun 24;11(1):3276
pubmed: 32581219
Mol Cell. 2019 Feb 7;73(3):429-445.e7
pubmed: 30612879
Curr Opin Immunol. 2018 Oct;54:93-101
pubmed: 29986303
Front Immunol. 2020 Sep 15;11:561948
pubmed: 33042141
EMBO Rep. 2020 Nov 5;21(11):e51787
pubmed: 33135287
EMBO J. 2020 Jul 1;39(13):e104926
pubmed: 32510692
Nat Immunol. 2019 May;20(5):527-533
pubmed: 30962589
PLoS One. 2014 Mar 13;9(3):e91522
pubmed: 24626347